Lirafugratinib not checked
Elevar Therapeutics · RLY-4008
FollowEvery change as it happens, and a Monday email
Trials
1 active
2 in total · 2 in the EU
What this is
- How it works
- Blocks a kinase, an enzyme that passes "grow" or "activate" signals inside cells. Most are cancer drugs.-tinib: tyrosine kinase inhibitors WHO name stem
- Main trialPhase 2
- “The goal of this clinical trial is to evaluate if lirafugratinib is efficacious and safe to treat adult patients with previously treated, unresectable, locally advanced or metastatic solid tumors (excluding cholangiocarcinoma) harboring FGFR2 fusion or rearrangement. Participants will: * Take lirafugratinib regularly as instructed by their study doctor. * Visit the clinic as instructed for checkups and tests. * Keep a diary recording each time a dose of lirafugratinib is taken.”In the company’s words, NCT07359820 on ClinicalTrials.gov
- Other names
- RLY-4008
Other drugs for FGFR2 Gene Fusion/Rearrangement
- FutibatinibTaiho · Phase 2/3
- TinengotinibTransThera Sciences (Nanjing), Inc. · Phase 3
- CTX-009Compass Therapeutics · Phase 2/3
- NanvuranlatJ-Pharma Co., Ltd. · Phase 3
- IvosidenibServier Bio-Innovation LLC · Phase 3
- ZanidatamabJazz Pharmaceuticals · Phase 3
Coming up1
- Sep 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | Sep 2027 | A Study of Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement | |
| Phase 1/2Completed | 5 Sep 2025 | REFOCUS: A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced Solid Tumors |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026